Autoantibodies against tumour suppressor protein p53 in pleural effusions of patients with tuberculosis pleurisy

• Published in: Annals of clinical biochemistry Vol. 44; no. Pt 1; p. 57
• Main Authors: Wang, L, Chang, Y-H, Lee, Y-L, Shih, C-M, Hsu, Y-T, Shen, G-H, Haung, M-L, Shiau, M-Y
• Format: Journal Article
• Language: English
• Published: England 01.01.2007
• Subjects: Adult; Aged; Aged, 80 and over; Autoantibodies - immunology; Female; Humans; Male; Middle Aged; Mutation; Pleural Effusion - immunology; Recombinant Fusion Proteins - genetics; Recombinant Fusion Proteins - immunology; Tuberculosis, Pleural - immunology; Tumor Suppressor Protein p53 - genetics; Tumor Suppressor Protein p53 - immunology
• ISSN: 0004-5632
• DOI: 10.1258/000456307779595986

Autoantibodies against the p53 proteins (p53 Abs) can be detected in the serum, ascites, saliva and pleural effusions of various malignant patients. It is suggested that p53 Abs in pleural effusions might have some value for tumour diagnosis, prognosis or monitoring. The present study investigated the prevalence of p53 Abs in the pleural effusions of 90 patients with various diseases. Patients with suspicious pleural effusions in chest film received thoracocentesis and their pleural effusions were collected. The presence of p53 Abs in effusion was detected by immunoblotting. Differences of p53 Abs with respect to the patient's age, gender, white blood cell count, lactate dehydrogenase, total proteins and adenosine deaminase scores were calculated by chi2-test. p53 Abs were detected in 14.4% (13/90) of our patients, with prevalences of 10.5% (6/57) and 21.2% (7/33) among patients with benign and malignant diseases, respectively. Notably, 16.1% (5/31) of patients with tuberculosis pleurisy were positive for p53 Abs. These five patients had no history of cancer and, so far, have had no manifestations related to tumorigenesis. As far as we know, this is the first report regarding the detection of p53 Abs in pleural effusions from patients with tuberculosis pleurisy.